Dr. John Cush RheumNow
3 years 9 months ago
RA Topic Panel
RheumNow recaps the best & most interesting data presented at #ACR22 in RA. Panelists: Drs.Conway, Najm, Liew, Pope, Segan
Follow: @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan
https://t.co/GMqRmF2yXA https://t.co/WmYRTp49Rv
Dr. John Cush RheumNow
3 years 9 months ago
Proposed Cancer Screening for Inflammatory Myositis Patients
11/12's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer.
https://t.co/JlGGZ6UnOc https://t.co/86OnuLINPy
Discussions regarding family planning, contraception, and pregnancy should be approached at each clinic visit to ensure providers understand patients’ personal goals. These conversations have the potential to decrease the risk of unplanned pregnancies. However, rheumatologists may need to manage unplanned pregnancies and the impacts of accidental teratogenic exposure.
Since reduced proteinuria at one year is the best predictor of improved long-term renal outcomes in lupus nephritis, is there rationale to set a tighter treatment target?
Dr. John Cush RheumNow
3 years 9 months ago
RheumNow Rheumatology Roundup
Dr. Jack Cush and Dr. Arthur Kavanaugh discuss, dissect and deliberate the sessions and data presented at the #ACR22 meeting in Philadelphia.
https://t.co/ppe5I5upvj https://t.co/su4SOS7MAg
Dr. John Cush RheumNow
3 years 9 months ago
Monday #ACR22 Daily Recap
https://t.co/QZTag5Hyol https://t.co/rgpxI9AOHP
Dr. John Cush RheumNow
3 years 9 months ago
FDA is investigating risk of severe hypocalcemia in dialysis patients taking Prolia (denosumab). After an interim safety data review reports of hypocalcemia w/ advanced CKD. Monitor Ca, use Ca & vit D supplements. Await further FDA information https://t.co/QMOtYs0eBY https://t.co/wzhIg53kCs
Dr. John Cush RheumNow
3 years 9 months ago
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at #ACR22
https://t.co/DEUykGt8pT https://t.co/sz8GRRGrPH
Dr. John Cush RheumNow
3 years 9 months ago
Do oral JAKs in atopic dermatitis cause VTE? Meta-analysis (15 RCTs, 466 993 pts) does NOT show increased risk of VTE associated with AD & JAK inhibitors (HR 0.95) w/ low VTE incidence (0.05%) w/ JAKi and (0.03%) placebo. https://t.co/mO2DHzjVJw https://t.co/aaC82UStob
Dr. John Cush RheumNow
3 years 9 months ago
Photovoice: A New Visual Research Method in Lupus
Dr. Bella Mehta ( @bella_mehta) talks with Dr. Candace Feldman about Abstract 1099: Empowering Patients with Lupus Through Their Photographs at #ACR22.
https://t.co/tPizbi16Om https://t.co/lYUXaGEerA
Catherine Sims, MD DrCassySims
3 years 9 months ago
Is toci an option in refractory PMR? #ACR22
📍double-blind RCT
💪101 pts w/GC-resistant PMR (mod. dz on pred. < 10 mg)
💉toci 8 mg/kg q4w + pred taper vs. placebo + pred taper over 24w
🌟49% in toci group stopped pred at week 24 vs. 20% in placebo
🌟AE similar b/t groups
